Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood

Frontiers in Immunology

Immunology

Stefan Beissert¹  Louisa Fennen¹  Claudia Günther¹  Sarah Rösing¹  Min Ae Lee-Kirsch²  Christine Wolf²  Martin Aringer³ 

[1] Department of Dermatology, University Hospital, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany;Department of Pediatrics, University Hospital, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany;Division of Rheumatology, Department of Medicine III, University Medical Center Hospital TU Dresden, Dresden, Germany;

关键词: interferon;    IFN score;    cutaneous lupus;    anifrolumab;    CLASI;   

DOI  :  10.3389/fimmu.2023.1253279

 received in 2023-07-05, accepted in 2023-08-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Cutaneous lupus erythematosus (CLE), the main manifestation of systemic lupus erythematosus (SLE), is driven by type I interferons (IFNs) and often only partially responds to conventional therapies. Treatment of seven SLE patients with the monoclonal antibody anifrolumab induced fast and sustained remission of previously refractory CLE lesions, beginning within the first weeks of treatment. Decline in CLASI-A score was paralleled by a reduction in IFN score determined by mRNA expression of seven IFN-stimulated genes (ISGs) in blood. These data suggest that a subset of ISGs could be a valuable biomarker in CLE.

【 授权许可】

Unknown   
Copyright © 2023 Günther, Wolf, Fennen, Rösing, Beissert, Aringer and Lee-Kirsch